Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AAPG vs IONS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IONS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

IONS Overall Winner 6-Pillar Tally: AAPG 2 – 4 IONS Matrix Metrics: AAPG 3 – 7 IONS

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 50.2/100 (HOLD) at $13.43 (9.7x Forward P/E, -219.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.75 (90.9x Forward P/E, -58.8% operating margin).

  • Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAPG vs IONS
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$13.43
-8.14% 1D
Market Cap $1.4B
TTM Revenue $643M
Forward P/E 9.7x
Beta / 30D Vol 1.32β · 70% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 58.0 Fund 60.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $14.94 · SMA50: $15.31
IONS NASDAQ Head-to-Head Winner
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.75
-1.08% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07

6-Pillar Scorecard Institutional Category Breakdown (AAPG 2 – 4 IONS)

Columns: Metric · AAPG · IONS
1. Valuation Multiples AAPG
Forward P/E 9.7x 90.9x
Trailing P/E 9.7x 90.9x
PEG Ratio N/M N/M
EV / Revenue 2.2x 6.2x
2. Growth & Scale IONS
Revenue Growth (YoY) +29.3% +54.9%
Earnings Growth (YoY) +0.0% -43.7%
TTM Revenue (USD) $643M $960M
Market Cap $1.4B $4.7B
3. Profitability & Quality IONS
Gross Margin 93.9% 3.0%
Operating Margin -219.5% -58.8%
Net Profit Margin -228.5% -56.9%
Return on Equity (ROE) -236.6% -108.0%
4. Balance Sheet & Cash Flow IONS
Cash Generation (TTM) -$1.34B EBITDA -$623M
Cash Flow Margin N/A -64.9%
Net Cash / Leverage $0.89 Book/Sh · -236.6% ROE $1.33B Net Debt (4.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AAPG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 59.9% (17th %ile)
Put/Call OI Skew Thin ADR Chain 1.81x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity N/A 61.8% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAPG (3) vs IONS (7)
Institutional Metric AAPG IONS Criterion Row Edge
Market Capitalization
Scale
$1.4B $4.7B Larger Scale IONS
Trailing P/E Ratio
Valuation
9.7x 90.9x Lower Multiple AAPG
Forward P/E Ratio
Valuation
9.7x 90.9x Lower Multiple AAPG
Revenue Growth (YoY)
Growth
+29.3% +54.9% Higher Growth IONS
Operating Margin (TTM)
Profitability
-219.5% -58.8% Higher Margin IONS
Net Profit Margin
Profitability
-228.5% -56.9% Higher Margin IONS
Return on Equity (ROE)
Capital Efficiency
-236.6% -108.0% Higher ROE IONS
52-Week Range Position
Momentum
0% ($13–$34) 2% ($27–$87) Stronger Trend IONS
Beta / 30D Volatility
Risk Regime
1.32β · 70% Vol 0.18β · 86% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 63.9 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$643M $960M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.9% 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.2x EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) -$623M ($1.33B Net Debt (4.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAPG +20.44 pp
AAPG: -12.62% · IONS: -33.06%
3M Horizon AAPG +25.58 pp
AAPG: -26.21% · IONS: -51.79%
6M Horizon AAPG +28.57 pp
AAPG: -33.45% · IONS: -62.02%
1Y Horizon IONS +1.28 pp
AAPG: -60.12% · IONS: -58.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs IONS. Trailing 12-month operating profitability (AAPG -219.5% vs IONS -58.8%) and valuation multiples (AAPG 9.7x vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 9.7x
IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ AAPG vs IONS Key Questions & Quantitative Answers

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 50.2/100 (HOLD) at $13.43 (9.7x Forward P/E, -219.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.75 (90.9x Forward P/E, -58.8% operating margin). Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: AAPG posts +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). On trailing 12-month operating scale, AAPG generates $643M in USD-normalized revenue versus $960M for IONS. In operating R&D and SG&A reinvestment, AAPG deploys N/A (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.

AAPG screens cheaper on headline valuation multiples. AAPG trades at 9.7x Forward P/E, 9.7x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (unreported EBITDA margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPG (-236.6% ROE) versus IONS (-108.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.32β · 70% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Ascentage Pharma Group International American Depository Shares (AAPG) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.